A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

Shahneen Sandhu; K. Papadopoulos; Peter C.C. Fong; Amita Patnaik; Christina Messiou; David Olmos; George Wang; Brenda Tromp; Thomas A. Puchalski; Frances R. Balkwill; Birge Berns; Shobha Seetharam; Johann S. de Bono; Anthony W. Tolcher

doi:10.1007/s00280-013-2099-8

Back

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

Article 2013 en

Related publications

Article2009

First-in-human, first-in-class, phase I study of a human monoclonal antibody CNTO 888 to the CC-chemokine ligand 2 (CCL2/MCP-1) in patients with solid tumors

Shahneen Sandhu, Peter C.C. Fong, Sophia Frentzas, Amita Patnaik, K. Papadopoulos, Brenda Tromp, Thomas A. Puchalski, Birge Berns, Anthony W. Tolcher, Johann S. de Bono

Article2010

Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.

Martin Förster, Amita Patnaik, Shahneen Sandhu, K. Papadopoulos, Brenda Tromp, Christina Messiou, Frances R. Balkwill, Birge Berns, Johann S. de Bono, A. W. Tolcher

Preprint2025

Table 2 from Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

Philippe A. Cassier, Mitesh J. Borad, Sunil Sharma, Bertrand Dubois, Christophe Caux, Fumiyoshi Okano, Daniel D. Von Hoff, Jean Yves Blay

Preprint2025

Figure 2 from Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

Philippe A. Cassier, Mitesh J. Borad, Sunil Sharma, Bertrand Dubois, Christophe Caux, Fumiyoshi Okano, Daniel D. Von Hoff, Jean Yves Blay

Article2025

Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

Philippe A. Cassier, Mitesh J. Borad, Sunil Sharma, Bertrand Dubois, Christophe Caux, Fumiyoshi Okano, Daniel D. Von Hoff, Jean Yves Blay

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

Discussion(0)

Related publications

First-in-human, first-in-class, phase I study of a human monoclonal antibody CNTO 888 to the CC-chemokine ligand 2 (CCL2/MCP-1) in patients with solid tumors

Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.

Table 2 from Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

Figure 2 from Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors

Phase I First-in-Human Study of TRK-950, an IgG1 Antibody Specific to CAPRIN-1, in Patients with Advanced Solid Tumors